A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis

S. De Vita, L. Quartuccio, M. Isola, C. Mazzaro, P. Scaini, M. Lenzi, M. Campanini, C. Naclerio, A. Tavoni, M. Pietrogrande, C. Ferri, M. T. Mascia, P. Masolini, A. Zabotti, M. Maset, D. Roccatello, A. L. Zignego, P. Pioltelli, A. Gabrielli, D. FilippiniO. Perrella, S. Migliaresi, M. Galli, S. Bombardieri, G. Monti

Research output: Contribution to journalArticle

Abstract

Objective To conduct a long-term, prospective, randomized controlled trial evaluating rituximab (RTX) therapy for severe mixed cryoglobulinemia or cryoglobulinemic vasculitis (CV). Methods Fifty-nine patients with CV and related skin ulcers, active glomerulonephritis, or refractory peripheral neuropathy were enrolled. In CV patients who also had hepatitis C virus (HCV) infection, treatment of the HCV infection with antiviral agents had previously failed or was not indicated. Patients were randomized to the non-RTX group (to receive conventional treatment, consisting of 1 of the following 3: glucocorticoids; azathioprine or cyclophosphamide; or plasmapheresis) or the RTX group (to receive 2 infusions of 1 gm each, with a lowering of the glucocorticoid dosage when possible, and with a second course of RTX at relapse). Patients in the non-RTX group who did not respond to treatment could be switched to the RTX group. Study duration was 24 months. Results Survival of treatment at 12 months (i.e., the proportion of patients who continued taking their initial therapy), the primary end point, was statistically higher in the RTX group (64.3% versus 3.5% [P <0.0001]), as well as at 3 months (92.9% versus 13.8% [P <0.0001]), 6 months (71.4% versus 3.5% [P <0.0001]), and 24 months (60.7% versus 3.5% [P <0.0001]). The Birmingham Vasculitis Activity Score decreased only after treatment with RTX (from a mean ± SD of 11.9 ± 5.4 at baseline to 7.1 ± 5.7 at month 2; P <0.001) up to month 24 (4.4 ± 4.6; P <0.0001). RTX appeared to be superior therapy for all 3 target organ manifestations, and it was as effective as conventional therapy. The median duration of response to RTX was 18 months. Overall, RTX treatment was well tolerated. Conclusion RTX monotherapy represents a very good option for severe CV and can be maintained over the long term in most patients.

Original languageEnglish
Pages (from-to)843-853
Number of pages11
JournalArthritis and Rheumatism
Volume64
Issue number3
DOIs
Publication statusPublished - Mar 2012

    Fingerprint

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Pharmacology (medical)

Cite this

De Vita, S., Quartuccio, L., Isola, M., Mazzaro, C., Scaini, P., Lenzi, M., Campanini, M., Naclerio, C., Tavoni, A., Pietrogrande, M., Ferri, C., Mascia, M. T., Masolini, P., Zabotti, A., Maset, M., Roccatello, D., Zignego, A. L., Pioltelli, P., Gabrielli, A., ... Monti, G. (2012). A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis and Rheumatism, 64(3), 843-853. https://doi.org/10.1002/art.34331